Clinical First Flow Neuroscience offers an FDA approved at-home tDCS treatment for depression backed by a pivotal Nature Medicine RCT and extensive real-world evidence, presenting a compelling value proposition for payers, clinics, and telehealth platforms seeking scalable, evidence-based neuromodulation solutions.

Global Accessibility With a focus on making brain stimulation accessible worldwide as a standalone or adjunct therapy, there are sales opportunities with healthcare systems, corporate wellness programs, and regional distributors aiming to expand at-home treatment options.

Regulatory & Quality ISO 9001 certification and a history of regulatory approval suggest reliability for procurement and vendor risk assessments, making Flow a suitable partner for contracted research organizations, hospitals, and managed care organizations prioritizing quality.

Strategic Funding Past investments from Khosla Ventures and others, plus visible clinical trial partnerships, indicate strong investor backing and credibility that can be leveraged in conversations with potential enterprise customers seeking vetted, growth-stage health tech vendors.

Expansion Signals Active branding updates and ongoing clinical trial activity imply momentum and product maturation, creating opportunities to pitch pilot programs, co-development with research networks, and inclusion in care pathways for depression treatment.